Why the study?
Impella CP can cause significant hemolysis that may persist despite proper device positioning, volume management, and full anticoagulation.
Does upgrading to Impella 5.0 or 5.5 reduce hemolysis in patients with cardiogenic shock experiencing refractory hemolysis on Impella CP support?
Does upgrading to Impella 5.0 or 5.5 reduce hemolysis in patients with cardiogenic shock experiencing refractory hemolysis on Impella CP support?
Upgrading from Impella CP to Impella 5.0 or 5.5 effectively resolves refractory hemolysis and may prevent further kidney damage in patients with cardiogenic shock.
Answers are grounded in this paper and cite their sources.
May support Impella upgrade for refractory hemolysis; hypothesis-generating case series requiring prospective confirmation before practice change.
The Impella CP (Abiomed Inc., Danvers, MA) is widely used in cardiac catheterization laboratories for patients presenting with cardiogenic shock, but it is also known to cause significant hemolysis. The risk of hemolysis can be reduced by properly positioning the device, ensuring an adequate volume status, and using full anticoagulation strategies; however, in some cases hemolysis persists. We present a case series of eight patients that were diagnosed with cardiogenic shock, underwent Impella CP placement, and then suffered from refractory hemolysis which was treated by upgrading the Impella device to the 5.0 or 5.5 version. Fifty percent (4/8) of the patients in this series were already receiving continuous renal replacement therapy, and the levels of plasma free hemoglobin (pFHb) and lactate dehydrogenase continued to increase after the implantation of the Impella CP. The median time between Impella CP placement and the diagnosis of refractory hemolysis was 16.5 hours (interquartile range [IQR], 8.0-26.0). The median time between the diagnosis of hemolysis to Impella upgrade was 6.0 hours (IQR, 4.0-7.0). A total of 87.5% (7/8) of patients experienced a drop in pFHb to below 40 mg/dl at 72 hours post-Impella upgrade, and they were discharged without any further need of dialysis. One patient expired due to irreversible multiple organ failure. We propose that early identification of hemolysis by close monitoring of pFHb and upgrading to the Impella 5.5 reduces hemolysis, prevents further kidney damage, and significantly improves clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Armas et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: